Image: DevdiscourseReuters Health News Summary
• Manipal Health Enterprises' $960.4 million IPO was oversubscribed, driven largely by institutional investors, while Glenmark Pharma reported a 53.6% increase in quarterly profits. • An FDA advisory panel voted on Thursday to support trial results for Replimune's skin cancer drug, RP1, following two previous FDA rejections. • The FDA had previously denied approval in April due to a lack of a control group and insufficient evidence of the drug's effectiveness.
devdiscourse.com